Skip to main content

Millipore Exploring Alternatives Following News of Acquisition Bid

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Millipore said late last night that its board of directors is evaluating "strategic alternatives to enhance shareholder value," including a potential merger or sale of the company.

Millipore's statement comes two days after Bloomberg reported that Thermo Fisher Scientific had made a $6 billion bid for the firm. Millipore did not respond to a request from GenomeWeb Daily News for comment earlier this week, while Thermo Fisher officials said they would not comment on rumors.

Millipore confirmed that it has hired Goldman Sachs as its financial advisor and Cravath, Swaine & Moore as its legal advisor to assist the board in its evaluation.

Millipore also said that it has not set a timetable for completing the evaluation and cannot assure that it will lead to any transaction.

In early Wednesday trade on the New York Stock Exchange, shares of Millipore were up 3 percent at $91.50. Its shares are up 28 percent for the week.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.